Novel chemotherapy approaches for cervical cancer

Abstract

Cancer of the cervix is the second most common malignancy among women worldwide. The last 20 years have lead to numerous advances in the medical management of locally advanced cervical cancer, including preventive vaccination, chemoradiation, and neoadjuvant chemotherapy. The treatment of metastatic disease is palliative at best. Platinum‐based chemotherapy remains the standard of care for inoperable patients who have recurrent disease. However, because most patients initially receive concomitant platinum‐based therapy with radiation, many recurrent tumors are refractory to platinum. The use of novel therapeutic approaches targeted to the carcinogenic processes that leads to the ontogenesis of cervical cancer should be promoted in clinical studies to improve patient outcomes. Cancer 2009; 115:3166–80. © 2009 American Cancer Society.

Protodioscin Induces Apoptosis Through ROS-Mediated Endoplasmic Reticulum Stress via the JNK/p38 Activation Pathways in Human Cervical Cancer Cells

“…Nevertheless, effective treatment options for cervical cancer patients are limited. The current approach to treating cervical cancer includes surgery, radiation treatment, and cytotoxic chemotherapy [2]. Identification of the molecular mechanisms underlying novel targeted therapeutic strategies is therefore an important objective for improved treatment of cervical cancer patients.…”

Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions

“…bevacizumab [29,30], pazopanib [31], or cetuximab [32]), may enhance outcome, there is the potential that unique toxicities may be observed [7], delaying or preventing the delivery of radiation, the single most important component of this strategy.…”

“…Despite several decades of intensive research, including the conduct of numerous phase 3 randomized trials, the impact of chemotherapy on the natural history of advanced cervix cancer is appreciated to be (at best) quite modest [1,2,3,4,5,6,7]. …”

Neoadjuvant Chemotherapy in Gynecologic Cancers

“…The rationale of giving neoadjuvant chemotherapy before radiation therapy included reducing tumor volume and radio-sensitizing tumors by decreasing the hypoxic cell fraction in large tumors (Movva et al, 2009). However, several randomized trials of such treatment revealed no survival advantage compared with radiation therapy alone (Chiara et al, 1994;Herod et al, 2000;Lacava et al, 1997;Leborgne et al, 1997;Sundfor et al, 1996;Souhami et al, 1991;Symonds, 2000;Tattersall et al, 1992;Tattersall et al, 1995).…”